Outlook Therapeutics (NASDAQ:OTLK) posted a net loss attributable to common stockholders of $23.1 million, or $0.38 per basic and diluted share, for the fiscal first quarter ended December 31, 2025.
Teva Pharmaceutical Industries (NYSE:TEVA) and Sanofi (NASDAQ:SNY) announced a major clinical victory on Tuesday, revealing that their investigational antibody, duvakitug (formerly TEV-574), successfully maintained disease control in patients with inflammatory bowel disease (IBD) for nearly a full year.
Medtronic (NYSE:MDT) reported third-quarter fiscal 2026 revenue of $9.017 billion, an increase of 8.7% as reported and 6.0% on an organic basis, surpassing the midpoint of its guidance by 50 basis points and marking the highest enterprise revenue growth in the past 10 quarters.
Harmony Biosciences Holdings (NASDAQ:HRMY) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for WAKIX® (pitolisant) to treat cataplexy in pediatric patients aged six years and older.
Pfizer (NYSE:PFE) today reported positive topline results from Cohort 3 of its pivotal Phase 3 BREAKWATER trial, marking a significant milestone in the treatment of one of the most aggressive forms of colorectal cancer.
Palatin Technologies (NYSE:PTN) reported its fiscal second-quarter 2026 results on Tuesday, marking a critical operational pivot as the biopharmaceutical firm clears financial hurdles and prepares to enter the highly competitive clinical landscape for weight-loss therapies.
NeoGenomics (NASDAQ:NEO) delivered solid fourth-quarter 2025 results, with consolidated revenue increasing 11% year over year to $190 million, driven by robust demand for its oncology-focused diagnostic testing services.
IDEAYA Biosciences (NASDAQ:IDYA) reported fourth-quarter and full-year 2025 results on Tuesday, setting a definitive timeline for a high-stakes clinical readout that could transition the precision medicine firm into a commercial-stage biotech.
Eli Lilly (NYSE:LLY) announced Monday that its drug Retevmo reached the primary goal of a late-stage study, significantly improving event-free survival for patients with a specific genetic form of early-stage lung cancer.
Citius Oncology (NASDAQ:CTOR) officially transitioned from a development-stage clinical trial outfit to a revenue-generating commercial entity this quarter, posting its first sales of the newly approved immunotherapy LYMPHIR.
Helus Pharma (NASDAQ:HELP) reported financial results and clinical progress for the third quarter of fiscal 2026 ended December 31, 2025, highlighting a solid cash position and advancing late-stage programs targeting major psychiatric indications.
Beyond Air (NASDAQ:XAIR) reported a surge in third-quarter revenue and a strategic pivot toward its core respiratory business, announcing a binding agreement to divest its autism and neuro-oncology subsidiary to XTL Biopharmaceuticals.
